Prevention of pneumococcal otitis media in chinchillas with human bacterial polysaccharide immune globulin
- PMID: 3366870
- PMCID: PMC266440
- DOI: 10.1128/jcm.26.4.755-759.1988
Prevention of pneumococcal otitis media in chinchillas with human bacterial polysaccharide immune globulin
Abstract
Clinical and experimental observations suggest that immune globulin may prevent otitis media (OM) in children. We performed experiments in chinchillas to test the hypothesis that human bacterial polysaccharide immune globulin (BPIG) might prevent OM caused by Streptococcus pneumoniae. Animals were given BPIG or saline intraperitoneally on day 0. On day 3 the epitympanic bulla was inoculated with S. pneumoniae type 7F. All 12 saline-treated and none of 12 BPIG-treated animals developed pneumococcal OM by day 7 (P less than 0.0001). Bacteremia developed in 6 of 12 saline- and 0 of 12 BPIG-treated animals (P = 0.007). Death with pneumococcal OM occurred within 28 days in 5 of 12 saline- and 0 of 12 BPIG-injected animals (P = 0.02). A chinchilla-specific immunoassay was used to show that surviving saline-injected animals developed serum anticapsular antibody; BPIG-treated animals had no detectable response. At levels of anticapsular immunoglobulin G similar to those of human adults, BPIG given systemically prevented pneumococcal OM and disseminated infection in chinchillas. BPIG may be of value in preventing human bacterial infection and may also inhibit development of antibody if it affects local infection or colonization. Specific immunoglobulin G antibody may provide an important antibacterial defense of mucosal surfaces of the respiratory tract.
Similar articles
-
Experimental otitis media in chinchillas following nasal colonization with type 7F Streptococcus pneumoniae: prevention after vaccination with pneumococcal capsular polysaccharide.J Infect Dis. 1979 Nov;140(5):716-23. doi: 10.1093/infdis/140.5.716. J Infect Dis. 1979. PMID: 43345
-
Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.J Infect Dis. 1996 Jan;173(1):119-27. doi: 10.1093/infdis/173.1.119. J Infect Dis. 1996. PMID: 8537648
-
Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin.N Engl J Med. 1987 Oct 8;317(15):923-9. doi: 10.1056/NEJM198710083171503. N Engl J Med. 1987. PMID: 2442610 Clinical Trial.
-
Otitis media: the chinchilla model.Microb Drug Resist. 1999 Spring;5(1):57-72. doi: 10.1089/mdr.1999.5.57. Microb Drug Resist. 1999. PMID: 10332723 Review.
-
Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease.J Infect Dis. 1992 Jun;165 Suppl 1:S129-33. doi: 10.1093/infdis/165-supplement_1-s129. J Infect Dis. 1992. PMID: 1588146 Review.
Cited by
-
Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.Antonie Van Leeuwenhoek. 1990 Jun;58(1):1-47. doi: 10.1007/BF02388078. Antonie Van Leeuwenhoek. 1990. PMID: 2195989 Review. No abstract available.
-
Evaluation of mixtures of purified Haemophilus influenzae outer membrane proteins in protection against challenge with nontypeable H. influenzae in the chinchilla otitis media model.Infect Immun. 1993 May;61(5):1950-7. doi: 10.1128/iai.61.5.1950-1957.1993. Infect Immun. 1993. PMID: 8478084 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical